Quantcast
Home > Quotes > KPTI
KPTI

Karyopharm Therapeutics Inc. Common Stock (KPTI) Quote & Summary Data

$5.61
*  
0.21
3.89%
Get KPTI Alerts
*Delayed - data as of Mar. 21, 2019 11:49 ET  -  Find a broker to begin trading KPTI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    KPTI Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 5.60 / $ 5.61
1 Year Target
13.5
Today's High / Low
$ 5.62 / $ 5.29
Share Volume
427,970
50 Day Avg. Daily Volume
1,894,275
Previous Close
$ 5.40
52 Week High / Low
$ 21.71 / $ 3.92
Market Cap
341,421,486
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -3.13
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
2.54

Intraday Chart

Shares Traded

Share Volume:
427,970
50 Day Avg. Daily Volume:
1,894,275

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.13

Trading Range

The current last sale of $5.61 is 43.11% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 5.62 $ 21.71
 Low: $ 5.29 $ 3.92

Company Description (as filed with the SEC)

We are a clinical-stage pharmaceutical company focused on the discovery, development and subsequent commercialization of novel, first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Our scientific expertise is focused on understanding the regulation of intracellular communication between the nucleus and the cytoplasm. We have discovered and are developing wholly-owned, novel, small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). These SINE compounds represent a new class of drug candidates with a novel mechanism of action that have the potential to treat a variety of diseases in areas of unmet medical need. Our SINE compounds were the first oral XPO1 inhibitors in clinical development.  ... More ...  



Risk Grade

Where does KPTI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 5.34
Open Date:
Mar. 21, 2019
Close Price:
$ 5.40
Close Date:
Mar. 20, 2019


Consensus Recommendation

Analyst Info